Open Access. Powered by Scholars. Published by Universities.®
- Publication Type
Articles 1 - 3 of 3
Full-Text Articles in Medical Specialties
Urodynamic Characteristics Of Patients With Urge Incontinence Treated With Sacral Neuromodulation And Adjunct Botulinum Toxin Injection, Brent Yelton, Jason Gilleran
Urodynamic Characteristics Of Patients With Urge Incontinence Treated With Sacral Neuromodulation And Adjunct Botulinum Toxin Injection, Brent Yelton, Jason Gilleran
Posters
Sacral neuromodulation (SN) and intradetrusor botulinum toxin (BTX) are effective treatments for refractory overactive bladder (OAB) and urge incontinence (UI).1 The decision on which treatment to use is based on several factors. Urodynamics (UDS) have not been proven to determine who will respond to SN. Detrusor overactivity (DO) suggests that BTX may be more effective, given its direct role on muscle. The purpose of this study is to determine if presence and severity of DO on UDS is associated with failure of SN and response to BTX.
The Incidence Of New Or Worsening Oab Symptoms In Patients With Prior Sars Cov-2 Infection, Ly Hoang Roberts, Bernadette Zwaans, Priya Padmanabhan
The Incidence Of New Or Worsening Oab Symptoms In Patients With Prior Sars Cov-2 Infection, Ly Hoang Roberts, Bernadette Zwaans, Priya Padmanabhan
Website/Multimedia Contributions
No abstract provided.
Incomplete Bladder Emptying And Urinary Tract Infections After Onabotulinumtoxina Injection For Overactive Bladder In Men And Women: Multi-Institutional Collaboration From The Sufu Research Network, William Stuart Reynolds, Anne M. Suskind, Jennifer T. Anger, Benjamin M. Brucker, Anne Pelletier Cameron, Priya Padmanabhan
Incomplete Bladder Emptying And Urinary Tract Infections After Onabotulinumtoxina Injection For Overactive Bladder In Men And Women: Multi-Institutional Collaboration From The Sufu Research Network, William Stuart Reynolds, Anne M. Suskind, Jennifer T. Anger, Benjamin M. Brucker, Anne Pelletier Cameron, Priya Padmanabhan
Conference Presentation Abstracts
Introduction: OnabotulinumtoxinA (BTX) is an effective third-line therapy for overactive bladder (OAB), however the potential for adverse events may prevent patients from initiating therapy. The objective of this study is to report rates of incomplete emptying and urinary tract infection (UTI) in men and women undergoing BTX for OAB and to identify potential risk factors for these adverse events. Methods: Eleven clinical sites performed an IRBapproved retrospective study of adult women and men undergoing first-time BTX injection (100 units) for non-neurogenic OAB in 2016. Exclusions included: post void residual (PVR) >150ml, prior BTX, pelvic radiation, or catheterization. Clinical data was …